M05BA06 • ibandronic acid • Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates
Ibandronic acid is a medication from the bisphosphonate class used for the prevention and treatment of osteoporosis, particularly in postmenopausal women, to reduce the risk of bone fractures, especially in the spine. It is also used to treat hypercalcemia associated with bone metastases in certain types of cancer.
Ibandronic acid works by inhibiting the activity of osteoclasts, the cells responsible for bone resorption, helping to maintain bone density and prevent bone loss. It is available in tablet or injection form, with administration being periodic (monthly or quarterly, depending on the indication).
Side effects may include muscle or joint pain, gastrointestinal irritation (such as heartburn or nausea), and, in rare cases, osteonecrosis of the jaw. It is important to take the medication as directed by a doctor, and patients should remain upright for at least 30-60 minutes after oral administration to reduce the risk of esophageal irritation.
Substance: ibandronic acid
Date of last drug list: 01-01-2019
Commercial code: W62605001
Concentration: 3mg
Pharmaceutical form: injection solution in pre-filled syringe
Quantity: 1
Product type: generic
Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.